[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Thomson-BIOSIS in Discussions
- To: liblicense-l@lists.yale.edu
- Subject: Thomson-BIOSIS in Discussions
- From: Ann Okerson <ann.okerson@yale.edu>
- Date: Mon, 20 Oct 2003 17:33:24 -0400 (EDT)
- Reply-to: liblicense-l@lists.yale.edu
- Sender: owner-liblicense-l@lists.yale.edu
Re-posted with permission. Of possible interest. ========================================== Outsell's e-briefs October 17, 2003 A Weekly Analysis of Events and Issues Affecting the Information Content Industry ========================================== Thomson in Final Talks with BIOSIS Secondary scientific publisher BIOSIS announced in May that it would pursue a strategic partner to carry the business forward. It has settled on Thomson Scientific, and its board announced this week that it has decided to pursue final negotiations for its sale to Thomson. Thomson has made significant investments in biosciences information recently. It acquired Current Drugs, and has integrated its Derwent patents content with the Web of Knowledge platform. Outsell data from our Pharmaceutical Industry benchmarks shows that BIOSIS, while a key source for information professionals, has a relatively low level of penetration to end-user desktops. Thomson has the IT muscle and the desktop reach to extend BIOSIS to the end users. [SNIP] ============================================================ David Curle Editor, e-briefs Outsell, Inc. mail to:dcurle@outsellinc.com ============================================================ Redistribution: Outsell's e-briefs is a subscription service. Individual subscribers may not redistribute to other persons without permission. Company subscribers have the right to distribute content freely within their companies/agencies/institutions, but not to persons outside their companies/agencies/institutions without permission. Subscriptions: Visit our Web site at http://www.outsellinc.com to order subscriptions to e-briefs. Rates are as follows: $495 for an individual subscription. Single reader with no redistribution rights. $2495 for a company subscription. Includes the right to redistribute to any number of readers within your company/institution. e-briefs is delivered on Fridays, 48 issues per year. ============================================================ ============================================================ Copyright 2003 Outsell, Inc. ============================================================
- Prev by Date: Walter/Yamamoto's Call for Boycott of Cell Press Journals
- Next by Date: BIOSIS/ZR to be sold?
- Previous by thread: Walter/Yamamoto's Call for Boycott of Cell Press Journals
- Next by thread: BIOSIS/ZR to be sold?
- Index(es):